The prostaglandin F2α analog fluprostenol attenuates the fibrotic effects of connective tissue growth factor on human trabecular meshwork cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 2-3, 2014, Pages 237-245

  Fuchshofer, Rudolf ^a   Kuespert, Sabrina ^a   Junglas, Benjamin ^a   Tamm, Ernst R ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; COLLAGEN TYPE 4A1; COLLAGEN TYPE 6; COLLAGEN TYPE 6A1; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; FLUPROSTENOL; GELATINASE A; PROSTAGLANDIN F2 ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; PROSTAGLANDIN F;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EXON; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; OPEN ANGLE GLAUCOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; WESTERN BLOTTING; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AQUEOUS HUMOR; BLOTTING, WESTERN; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; GLAUCOMA, OPEN-ANGLE; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

EID: 84898743254     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0205     Document Type: Article

References (77)

1. Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I., Pararajasegaram, R., Pokharel, G.P., and Mariotti, S.P. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82:844-851, 2004.
2. Quigley, H. A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80:389-393, 1996.
3. Quigley, H.A. Glaucoma. Lancet. 377:1367-1377, 2011.
4. Kwon, Y.H., Fingert, J.H., Kuehn, M.H., and Alward, W.L. Primary open-angle glaucoma. N. Engl. J. Med. 360:1113-1124, 2009.
5. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
6. Kass, M.A., Heuer, D.K., Higginbotham, E.J., Johnson, C.A., Keltner, J.L., Miller, JP., Parrish, R.K., 2nd, Wilson, M.R., and Gordon, M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713; discussion 829-730, 2002.
7. Leske, M.C., Heijl, A., Hussein, M., Bengtsson, B., Hyman, L., and Komaroff, E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121:48-56, 2003.
8. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126:487-497, 1998.
9. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 126:498-505, 1998.
10. Pfeiffer, N., Lamparter, J., Gericke, A., Grus, F.H., Hoffmann, E.M., and Wahl, J. Neuroprotection of medical IOP-lowering therapy. Cell Tissue Res. 353:245-251, 2013.
11. Tamm, E.R. The role of the ciliary body in aqueous humor dynamics: structural aspects. In: Besharse, J., Dana, R., Dartt, D., eds. Encyclopedia of the Eye. Oxford: Academic Press; 2009; p. 179-186.
12. Tamm, E.R., and Lütjen-Drecoll, E. Ciliary body. Microscop. Res. Tech. 33:390-439, 1996.
13. Tamm, E.R. The trabecular meshwork outflow pathways: structural and functional aspects. Exp. Eye Res. 88: 648-655, 2009.
14. Tamm, E.R. The trabecular meshwork outflow pathways. Functional morphology and surgical aspects. In: Shaarawy, T.M, Sherwood, M.B., Hitchings, R.A., Crowston, J.G., eds. Glaucoma. Philadelphia, PA: Saunders Elsevier; 2009; p. 31-44.
15. Alm, A., and Nilsson, S.F. Uveoscleral outflow-a review. Exp. Eye Res. 88:760-768, 2009.
16. Grant, W.M. Experimental aqueous perfusion in enucleated human eyes. Arch. Ophthalmol. 69:783-801, 1963.
17. Johnson, M. What controls aqueous humour outflow resistance? Exp. Eye Res. 82:545-557, 2006.
18. Fuchshofer, R., and Tamm, E.R. Modulation of extracellular matrix turnover in the trabecular meshwork. Exp. Eye Res. 88:683-688, 2009.
19. Tamm, E.R., and Fuchshofer, R. What increases outflow resistance in primary open-angle glaucoma? Surv. Ophthalmol. 52(Suppl 2):S101-S104, 2007.
20. Last, J.A., Pan, T., Ding, Y, Reilly, C.M., Keller, K., Acott, T.S., Fautsch, M.P., Murphy, C.J., and Russell, P. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 52: 2147-2152, 2011.
21. Crawford, K., and Kaufman, P.L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys: evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch. Ophthalmol. 105:1112-1116, 1987.
22. Nilsson SF, Sperber GO, Bill A. The effect of prostaglandin F2 alpha-1-isopropylester (PGF2 alpha-IE) on uveoscleral outflow. Prog. Clin. Biol. Res. 312:429-436, 1989.
23. Nilsson, S.F., Samuelsson, M., Bill, A., and Stjernschantz, J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 48:707-716, 1989.
24. Lütjen-Drecoll, E., and Tamm, E. The effects of ocular hypotensive doses of PGF2 alpha-isopropylester on anterior segment morphology. Prog. Clin. Biol. Res. 312:437-446, 1989.
25. Lütjen-Drecoll, E., and Tamm, E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2a. Exp. Eye Res. 47:761-769, 1988.
26. Lindsey, J.D., Kashiwagi, K., Boyle, D., Kashiwagi, F., Firestein, G.S., and Weinreb, R.N. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 15:869-875, 1996.
27. Ocklind, A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp. Eye Res. 67:179-191, 1998.
28. Tamm, E., Rittig, M., and Lütjen-Drecoll E. Elektronenmikroskopische und immunhistochemische Untersuchungen zur augendrucksenkenden Wirkung von Prostaglandin F2a. Fortschr. Ophthalmol. 87:623-629, 1990.
29. Sagara, T., Gaton, D.D., Lindsey, J.D., Gabelt, B.T., Kaufman, P.L., and Weinreb, R.N. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol. 117:794-801, 1999.
30. Toris, C.B., Zhan, G., Fan, S., Dickerson, J.E., Landry, T.A., Bergamini, M.V., and Camras, C.B. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J. Glaucoma 16:189-195, 2007.
31. Christiansen, G.A., Nau, C.B., McLaren, JW., and Johnson, D.H. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 111:1658-1662, 2004.
32. Wan, Z., Woodward, D.F., Cornell, C.L., Fliri, H.G., Martos, J.L., Pettit, S.N., Wang, J.W., Kharlamb, A.B., Wheeler, L.A., Garst,M.E., Landsverk, K.J., Struble, C.S., and Stamer, W.D. Bimatoprost, prostamide activity, and conventional drainage. Invest. Ophthalmol. Vis. Sci. 48:4107-4115, 2007.
33. Bahler, C.K., Howell, K.G., Hann, CR., Fautsch, M.P., and Johnson, D.H. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am. J. Ophthalmol. 145:114-119, 2008.
34. Junglas, B., Kuespert, S., Seleem, A.A., Struller, T., Ullmann, S., Bosl, M., Bosserhoff, A., Kostler J, Wagner, R., Tamm, E.R., and Fuchshofer, R. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. Am. J. Pathol. 180:2386-2403, 2012.
35. Ihn, H. Pathogenesis of fibrosis: role of TGF-b and CTGF. Curr. Opin. Rheumatol. 14:681-685, 2002.
36. Phanish, M.K., Winn, S.K., and Dockrell, M.E. Connective tissue growth factor-(CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 114:e83-e92, 2009.
37. Junglas, B., Yu, A.H., Welge-Lussen, U., Tamm, E.R., and Fuchshofer, R. Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells. Exp. Eye Res. 88:1065-1075, 2009.
38. Bean, G.W., and Camras, C.B. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv. Ophthalmol. 53(Suppl 1):S69-S84, 2008.
39. Fuchshofer, R., Yu, A.H.,Welge-Lüssen, U., and Tamm, E.R. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 48:715-726, 2007.
40. Husain, S., Jafri, F., and Crosson, C.E. Acute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC-and ERK-dependent process. Invest. Ophthalmol. Vis Sci. 46:1706-1713, 2005.
41. Weinreb, R.N., Lindsey, J.D., Marchenko, G., Marchenko, N., Angert, M., and Strongin, A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest. Ophthalmol. Vis. Sci. 45:4368-4377, 2004.
42. Gaton, D.D., Sagara, T., Lindsey, J.D., Gabelt, B.T., Kaufman, P.L., and Weinreb, R.N. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch. Ophthalmol. 119:1165-1170, 2001.
43. Tektas, O.Y., and Lütjen-Drecoll, E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp. Eye Res. 88:769-775, 2009.
44. Lütjen-Drecoll, E., Shimizu, T., Rohrbach, M., and Rohen, J.W. Quantitative analysis of "plaque material" in the inner and outer wall of Schlemm's canal in normal and glaucomatous eyes. Exp. Eye Res. 42:443-455, 1986.
45. Rohen, J.W., Lütjen-Drecoll, E., Flügel, C., Meyer, M., and Grierson, I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp. Eye Res. 56:683-692, 1993.
46. Lütjen-Drecoll, E., Rittig, M., Rauterberg, J., Jander, R., and Mollenhauer, J. Immunomicroscopical study of type VI collagen in the trabecular meshwork of normal and glaucomatous eyes. Exp. Eye Res. 48:139-147, 1989.
47. Rodrigues, M.M., Katz, S.I., Foidart, J.M., and Spaeth, GL. Collagen, factor VIII antigen, and immunoglobulins in the human aqueous drainage channels. Ophthalmology 87:337-345, 1980.
48. Babizhayev, M.A., and Brodskaya, M.W. Fibronectin detection in drainage outflow system of human eyes in ageing and progression of open-angle glaucoma. Mech. Ageing Dev. 47:145-157, 1989.
49. Picht, G., Welge-Luessen, U., Grehn, F., and Lütjen-Drecoll, E. Transforming growth factor-b2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch. Clin. Exp. Ophthalmol. 239:199-207, 2001.
50. Tripathi, R.C., Li, J., Chan, W.F.A., and Tripathi, B.J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-b2. Exp. Eye Res. 58:723-727, 1994.
51. Inatani, M., Tanihara, H., Katsuta, H., Honjo, M., Kido, N., and Honda Y. Transforming growth factor-b2 levels in aqueous humor of glaucomatous eyes. Graefes Arch. Clin. Exp. Ophthalmol. 239:109-113, 2001.
52. Min, S.H., Lee, T.I., Chung, Y.S., and Kim, H.K. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J. Ophthalmol. 20:162-165, 2006.
53. Ochiai, Y., and Ochiai, H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn. J. Ophthalmol. 46:249-253, 2002.
54. Ozcan, A.A., Ozdemir, N., and Canataroglu, A. The aqueous levels of TGF-beta2 in patients with glaucoma. Int. Ophthalmol. 25:19-22, 2004.
55. Fuchshofer, R., and Tamm, E.R. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res. 347:279-290, 2012.
56. Tomarev, S.I., Wistow, G., Raymond, V., Dubois, S., and Malyukova, I. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest. Ophthalmol. Vis. Sci. 44:2588-2596, 2003.
57. van Setten, G.B., Blalock, T.D., Grotendorst, G., and Schultz, G.S. Detection of connective tissue growth factor in human aqueous humor. Ophthalmic Res. 34:306-308, 2002.
58. Ho, S.L., Dogar, G.F., Wang, J., Crean, J., Wu, Q.D., Oliver, N., Weitz, S., Murray, A., Cleary, P.E., and O'Brien, C. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br. J. Ophthalmol. 89:169-173, 2005.
59. Wordinger, R.J., Fleenor, D.L., Hellberg, P.E., Pang, I.H., Tovar, T.O., Zode, G.S., Fuller, J.A., and Clark, A.F. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest. Ophthalmol. Vis. Sci. 48:1191-1200, 2007.
60. Fuchshofer, R., Stephan, D.A, Russell, P., and Tamm, E.R. Gene expression profiling of TGFbeta2-and/or BMP7-treated trabecular meshwork cells: identification of Smad7 as a critical inhibitor of TGF-beta2 signaling. Exp. Eye Res. 88:1020-1032, 2009.
61. Weinreb, R.N., Mitchell, M.D., and Polansky, J.R. Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone. Invest. Ophthalmol. Vis. Sci. 24:1541-1545, 1983.
62. Anthony, T.L., Pierce, K.L., Stamer, W.D., and Regan, J.W. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 39:315-321, 1998.
63. Yu, A.L., Fuchshofer, R., Kampik, A., and Welge-Lussen, U. Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues. Invest. Ophthalmol. Vis. Sci. 49:4872-4880, 2008.
64. Fuchshofer, R., Welge-Lussen, U., and Lütjen-Drecoll, E. The effect of TGF-b2 on human trabecular meshwork extracellular proteolytic system. Exp. Eye Res. 77:757-765, 2003.
65. Han, H., Kampik, D., Grehn, F., and Schlunck, G. TGF-b2-induced invadosomes in human trabecular meshwork cells. PLoS ONE 5;8:e70595, 2013.
66. Liang, Y., Li, C., Guzman, V.M., Evinger A.J. 3rd, Protzman C.E., Krauss A.H., Woodward D.F. Comparison of prostaglandin F2a, bimatoprost (prostamide), and Butaprost (EP2 agonist) on CYR61 and CTGF gene expression. J. Biol. Chem. 278:27267-27277, 2003.
67. Bradley, J.M., Vranka, J., Colvis, C.M., Conger, D.M., Alexander, J.P., Fisk, A.S., Samples, J.R., and Acott, T.S. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 39:2649-2658, 1998.
68. Browne, J.G., Ho, S.L., Kane, R., Oliver, N., Clark, A.F., O'Brien, C.J., and Crean, J.K. Connective tissue growth factor is increased in pseudoexfoliation glaucoma. Invest. Ophthalmol. Vis. Sci. 2011 May 27. [Epub ahead of print]
69. Sharif, N.A., Kelly, C.R., Crider, J.Y., Williams, G.W., and Xu, S.X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19:501-515, 2003.
70. Faulkner, R., Sharif, N.A., Orr, S., Sall, K., Dubiner, H., Whitson, J.T., Moster, M., Craven, E.R., Curtis, M., Pailliotet, C., Martens, K., and Dahlin, D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN. J. Ocul. Pharmacol. Ther. 26:147-156, 2010.
71. Alvarado, J., Murphy, C., and Juster, R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 91:564-579, 1984.
72. Grierson, I., and Howes, R.C. Age-related depletion of the cell population in the human trabecular meshwork. Eye 1:204-210, 1987.
73. Fuchshofer, R., Ullmann, S., Zeilbeck, L.F., Baumann, M., Junglas, B., and Tamm, E.R. Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury. Histochem. Cell Biol. 136:301-319, 2011.
74. Tian, B., Gabelt, B.T., Geiger, B., and Kaufman, P.L. The role of the actomyosin system in regulating trabecular fluid outflow. Exp. Eye Res. 88:713-717, 2009.
75. Tian, B., Geiger, B., Epstein, D.L., and Kaufman, P.L. Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest. Ophthalmol. Vis. Sci. 41:619-623, 2000.
76. Wiederholt, M., Thieme, H., and Stumpff, F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog. Retin. Eye Res. 19:271-295, 2000.
77. Stamer, W.D., Piwnica, D., Jolas, T., Carling, R.W., Cornell, C.L., Fliri, H., Martos, J., Pettit, S.N., Wang, J.W., and Woodward, D.F. Cellular basis for bimatoprost effects on human conventional outflow. Invest. Ophthalmol. Vis. Sci. 51:5176-5181, 2010.